Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.

JACC. Heart failure - 1 Aug 2021

Sharma Abhinav, Ofstad Anne Pernille, Ahmad Tariq, Zinman Bernard, Zwiener Isabella, Fitchett David, Wanner Christoph, George Jyothis T, Hantel Stefan, Desai Nihar, Mentz Robert J

Abstract excerpt

OBJECTIVES: Using latent class analysis (LCA) of EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), this study identified distinct phenotypes in subjects with type 2 diabetes (T2D) and cardiovascular (CV) disease and explored treatment effects across phenotypes. BACKGROUND: In the EMPA-REG OUTCOME trial, empagliflozin reduced risk of CV death or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Diseases
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Treatment and Management

Share to Double-Blind Method

Share to Heart Failure

Share to Pancreatic function and diabetes

Share to Phenotype

Share to Treatment Outcome

Source

Identifiers

PMID: 34325887
DOI: 10.1016/j.jchf.2021.03.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.PMID 34325887Read ↗

Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial.Semantic proximity Read ↗

Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.Semantic proximity Read ↗

Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudySemantic proximity Read ↗

Diabetic kidney disease phenotypes and the risk of cardiovascular events: The Silesia Diabetes-Heart Project.Semantic proximity Read ↗

Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies.Semantic proximity Read ↗

Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network StudySemantic proximity Read ↗

Risk of cardiovascular events associated with pathophysiological phenotypes of type 2 diabetes.Semantic proximity Read ↗

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesSemantic proximity Read ↗

Identifying clinical phenotype clusters in patients with coronary artery disease.Semantic proximity Read ↗

HFpEF as the Predominant and Underrecognized Heart Failure Phenotype in Type 2 Diabetes: Evidence from the DIABET-IC StudySemantic proximity Read ↗

RESEARCH PROTOCOL: Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitusSemantic proximity Read ↗

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.